Insider Transactions in Q2 2024 at Optimize Rx Corp (OPRX)
Insider Transaction List (Q2 2024)
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jun 07
2024
|
Ellen O'Connor Vos Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,286
+17.47%
|
-
|
Jun 07
2024
|
Patrick D Spangler Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,286
+22.61%
|
-
|
Jun 07
2024
|
James Paul Lang Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,286
+16.34%
|
-
|
Jun 07
2024
|
Cathy Klema Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,643
+50.0%
|
-
|
Jun 07
2024
|
Gregory D Wasson Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,286
+21.92%
|
-
|
Jun 05
2024
|
Ellen O'Connor Vos Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,061
+16.9%
|
-
|
Jun 05
2024
|
Patrick D Spangler Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,061
+23.82%
|
-
|
Jun 05
2024
|
James Paul Lang Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,061
+15.52%
|
-
|
Jun 05
2024
|
Gus D Halas Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,061
+11.06%
|
-
|
Jun 05
2024
|
Gregory D Wasson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,061
+22.82%
|
-
|
May 02
2024
|
Stephen L Silvestro Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
35,415
-32.71%
|
$354,150
$10.7 P/Share
|
May 02
2024
|
Stephen L Silvestro Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
90,000
+45.39%
|
-
|
Apr 18
2024
|
William J Febbo CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
782
-0.13%
|
$7,038
$9.35 P/Share
|
Apr 18
2024
|
William J Febbo CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
28,895
+4.73%
|
-
|
Apr 15
2024
|
William J Febbo CEO |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+10.03%
|
-
|